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ABSTRACT
This review presents detailed information about the
structure of triplet repeat RNA and addresses the
simple sequence repeats of normal and expanded
lengths in the context of the physiological and
pathogenic roles played in human cells. First, we
discuss the occurrence and frequency of various
trinucleotide repeats in transcripts and classify
them according to the propensity to form RNA
structures of different architectures and stabilities.
We show that repeats capable of forming hairpin
structures are overrepresented in exons, which
implies that they may have important functions.
We further describe long triplet repeat RNA as a
pathogenic agent by presenting human neurological
diseases caused by triplet repeat expansions in
which mutant RNA gains a toxic function.
Prominent examples of these diseases include
myotonic dystrophy type 1 and fragile
X-associated tremor ataxia syndrome, which are
triggered by mutant CUG and CGG repeats, respect-
ively. In addition, we discuss RNA-mediated patho-
genesis in polyglutamine disorders such as
Huntington’s disease and spinocerebellar ataxia
type 3, in which expanded CAG repeats may act as
an auxiliary toxic agent. Finally, triplet repeat RNA is
presented as a therapeutic target. We describe
various concepts and approaches aimed at the se-
lective inhibition of mutant transcript activity in
experimental therapies developed for repeat-
associated diseases.
INTRODUCTION
In the early 1990s, the identiﬁcation of a new class of
disease-causing mutations caused considerable excitement
in the community of human molecular geneticists. The
mutations were inherited trinucleotide repeat (TNR) ex-
pansions, and the associated disorders became known as
Trinucleotide Repeat Expansion Diseases (TREDs) (1).
Over 20 neurological diseases have now been assigned to
this group. Each disease is associated with a single defect-
ive gene, which triggers the process of pathogenesis
through aberrant expression or toxic properties of
mutant transcripts or proteins [reviewed in (2–4)].
Although researchers have been making efforts to
develop treatments for TREDs for nearly two decades,
they remain incurable.
TREDs include spinal and bulbar muscular atrophy
(SBMA) (5), fragile X syndrome (FXS) (6), myotonic dys-
trophy type 1 (DM1) (7), Huntington’s disease (HD) (8)
and a number of spinocerebellar ataxias (SCA) (9,10). The
ﬁrst years of research on pathogenic mechanisms in
TREDs resulted in clear mechanistic separation among
different groups of the disorders. However, recent
studies have begun to reveal that mutant RNA and
mutant protein can act in parallel and exert their toxicities
independently in some TREDs (11–13). Mutant tran-
scripts may contribute to the pathogenesis of diseases
driven by mutant proteins (11,12), and mutant proteins
may contribute to the pathogenesis of disorders known
as driven by toxic RNA (13). Thus, the long-standing
borders between distinct pathomechanisms in TREDs
are beginning to be crossed, and this crossing occurs in
both directions.
Much of the recent excitement brought to the ﬁeld of
TREDs may be attributed to the rapid progress of
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(14–16). All the approaches discussed here are aimed at
targeting triplet repeat RNA sequences with the goal of
disrupting their pathogenic interaction with sequestered
proteins, inhibiting translation from the mutant allele or
destroying mutant transcripts. In some of these
approaches, detailed information on the structure of the
target RNA is essential for the rational design of potent
reagents that may become useful therapeutic tools in the
future.
In this review, we summarize the results of detailed
structural studies of triplet repeats present in transcripts
of TRED genes, in either non-coding or protein coding
regions. Relevant structural information is given to illus-
trate involvement of RNA structure in the mechanism of
pathogenesis triggered by expanded repeats. Important
recent ﬁndings are also presented in the context of
TNR genomics. The genomic and transcriptomic perspec-
tives are shown to better understand the abundance
of various triplet repeats, i.e. their presence in the
cells in which pathology develops and where selective
targeting by various reagents must occur. The character-
istics of interactions between TRED transcripts and spe-
ciﬁc proteins are also presented, as these interactions
determine the downstream adverse effects of TNR
mutations.
TRIPLET REPEATS ARE FREQUENT MOTIFS IN
HUMAN TRANSCRIPTS
TNRs belong to simple sequence repeats (SSRs), also
known as short tandem repeats or microsatellites, and
are common motifs in the genomes of humans and
many other species (17). The repeats mutate at a very
high rate, are often polymorphic in length and functions
proposed for the repeats are related to their variable
length (18). They are copious not only in genomes but
also in transcriptomes, and their abundance may be
higher than originally thought due to the presence of bi-
directional transcription across the majority of human
genes and intergenic regions (19,20). Importantly, in
translated sequences, TNRs are selected preferentially
over dinucleotide or tetranucleotide repeats, because the
length variation of TNRs does not change the reading
frame (21).
Twenty different TNR motifs may potentially occur in
RNAs if homotrinucleotide motifs are excluded and dif-
ferent phases of individual motifs are combined. The great
abundance of some TNRs in cells raises questions about
what roles these sequences might play in transcripts (22).
TNRs differ in length, and the expression levels of their
host transcripts vary greatly. The structures formed by
TNRs in transcripts depend not only on the repeat
motif, and the number of its units, but also on the
presence of interruptions breaking the homogeneity of
the repeat tract (23). TNRs that have beneﬁcial structural
features and functional properties are positively selected
during evolution, and TNRs with deleterious features are
selected against (24).
A number of studies have been performed and many
resources developed to characterize the frequency and
location of SSRs (including TNRs) in the human
genome (17,25–27) and exome (28–33). The main ques-
tions that have been addressed are the following: how
many human mRNAs contain TNRs? At what fre-
quency do certain types of TNRs occur? What is the
length distribution of various TNRs in transcripts?
What is the preferred location of TNRs in mRNA?
And what are the known and putative functions of
these sequences?
Three independent studies have provided the answers to
these questions by identifying TNRs in the human genome
reference sequence (27,29,34). In the most recent study,
32448 tracts of uninterrupted TNRs composed of six or
more repeated units were identiﬁed using the BLASTn
algorithm (29). The relative frequencies of different
TNR types were similar to those reported in earlier
genome-wide surveys that used different repeat length
and purity thresholds (25–27,34). As many as 1030
TNRs were identiﬁed in the exonic sequences of 878
genes. The TNRs that are strongly overrepresented in
exons are CNG (where N is any nucleotide), CGA and
AGG, whereas CTT, CAT, CAA, TAA and TTA are
robustly underrepresented (Figure 1A). The shortest
tracts are most prevalent, and the frequency of TNRs de-
creases roughly exponentially with their length. For the
majority of TNR types, the longest tracts are <20
repeated units. However, for some TNRs such as AAG,
several tracts >30 units have been identiﬁed (29). Of the
1030 exonic TNRs, 59% are located in the ORF, 28% are
in the 50-UTR and 13% are in the 30-UTR. The CCA,
CAG, CTG, CCT, AGG, AAG and ATG TNRs occur
most frequently in the open reading frame (ORF)
( 80%); AT-rich TNRs are more frequent in the 30-
UTR, whereas CCG and CGG repeats are most
frequent in the 5’-UTR (52% and 62%, respectively) (29).
To better characterize TNR sequences, their occurrence
and genetic polymorphism have been investigated (35–38).
Detailed information about triplet repeat length distribu-
tion in speciﬁc genes has been gathered experimentally for
CAG and CTG repeats (36). A population genotyping
study was conducted on 100 human genes selected to
contain the longest runs of these repeats. The results
demonstrated that very long and highly polymorphic
repeat tracts are rare in genes not known to be associated
with TREDs, which is in agreement with the results of a
previous bioinformatics survey (23).
Functional association studies have been performed to
gain some insight into the roles played by TNR-containing
genes. It was found that genes coding for (i) proteins
with transcription-related functions, (ii) proteins that
interact with nucleic acids and (iii) proteins with nuclear
localization are generally overrepresented among TNR-
containing genes (27,29,37). These results as well as
other lines of evidence suggest that the functions of
TNRs can be expressed not only through proteins, but
also at the DNA (24,35,39,40) and RNA (29,41–43)
levels. Furthermore, TNR functions in RNA may
strongly depend on the structures adopted by these
sequences.
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To provide a basis for a functional analysis of triplet
repeats in RNAs, the solution structures of oligoribonu-
cleotides (ORNs) composed of the reiterations of speciﬁc
triplets have been investigated under different experimen-
tal conditions using various methods. The ORNs that
were ﬁrst analyzed were four CNG motifs (N=A, C, G
or U) reiterated 17 times (44). All these ORNs were found
to form hairpin structures as demonstrated by chemical
and enzymatic structure probing. The stem of the CNG
repeat hairpin was shown to be composed of periodically
occurring C–G and G–C base pairs and single N–N base
mismatches. The hairpin loop was formed by either four
or seven nucleotides. With the exception of the CGG
repeat hairpin, the other three repeated CNG motifs
form ‘slippery’ hairpins (i.e. tend to form alternative align-
ments unless they are ﬁxed in one conformation by a G–C
clamp) (44). Recently, the structures of all 20 different
triplet motifs repeated either 17 or 20 times were subjected
to a comparative analysis using biochemical structure
probing as well as gel mobility analysis, and these struc-
tures were assigned to four classes (45). As shown in
Figure 1B, AGG and UGG repeats form the most stable
G-quadruplex structures; CGA, CGU and all CNG
repeats form hairpins that are more stable than those of
UAG, AUG, UUA, CUA and CAU repeats, whereas
CAA, UUG, AAG, CUU, CCU, CAA and UAA
repeats do not form any higher order structure. Further
analysis of the hairpin and G-quadruplex structure-
forming repeats was pursued using biophysical methods.
UV-monitored structure melting revealed the following
order of stability for CNG repeat hairpins: CGG>
CAG>CUG>CCG; the stabilities of the AGG and
UGG G-quadruplexes are roughly similar. CD spectra
have shown that both G-quadruplexes are formed by
parallel RNA strands (45). A shorter version of the
G-quadruplex forming AGG RNA repeats (GGA)4 was
also analyzed by NMR and CD (46,47). The intramolecu-
lar G-quadruplex was shown to be formed by a G:G:G:G
tetrad plane and a G(:A):G:G(:A):G hexad plane (47).
Other studies of triplet repeat ORN structures have
included UV melting and/or CD studies of all CNG
repeats or selected sequences of this group (48,49), gel
mobility analysis of CGG repeats (50,51) and NMR
studies of CGG repeats (52).
Crystal structures have been determined for short CUG
(53,54), CAG (55) and CGG (56) repeats, which form
intermolecular duplexes. The X-ray structures revealed
details of the molecular architecture of these duplexes
that are considered representative for stem portions of
the CUG, CAG and CGG repeat hairpins. From a struc-
tural biology perspective, the nature and consequences of
the periodic U:U, A:A and G:G mismatches were the most
interesting ﬁndings. In the CUG repeat crystal structure,
the U:U mismatches form stretched wobble interactions
having only one hydrogen bond between the carbonyl O4
atom of one uracil residue and the N3 imino group of the
opposite U residue (53). Similarly, in the CAG repeats,
only one hydrogen bond is formed between the opposing
adenine residues. This is an unusual and weak C2-H2 N1
bond. All the adenine residues are in the anti-conform-
ation and serve as both hydrogen bond donors and ac-
ceptors (55). In the non-canonical G:G pairs found in
CGG repeat duplexes, one guanosine residue is always
in syn and the other is in anti conformation, and they
form two hydrogen bonds, O6 N1H and N7 N2H. The
helical structures of CGG repeats are more stable than
those formed by CAG and CUG repeats (56).
Finally, an interesting correlation was found on
comparing the occurrence of different triplet repeats in
exons (described in a previous section) with their struc-
tures. As presented in Figure 1, TNRs that are strongly
overrepresented in exons belong to the hairpin forming
repeats, whereas underrepresented is the majority of
repeat types that do not form any stable structure. The
positive selection of repeats capable of forming hairpin
Figure 1. The occurrence of various triplet repeats in the human tran-
scriptome and their RNA structures. (A) Representation of TNRs
composed of at least six repeat units in RefSeq mRNA sequences
compared with the whole human genome sequence (17 out of 20
triplets are shown due to lack of CGT, CTA, TAG repeats in exons).
Bar colors correspond to the four classes of RNA structure as shown in
(B); (B) 20 different triplet repeat RNAs belong to four structural
classes. On the diagram, they are ordered from left to right according
to the increasing thermodynamic stability of their secondary structure:
seven TNRs are single stranded even at low temperature (4 C), ﬁve
AU-rich repeats form semi-stable hairpins in physiological conditions,
the next six GC-rich TNRs form stable hairpin structures and two
TNRs form the most stable quadruplexes.
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the regulation of gene expression, but the selection may
also be acting at the level of amino acid repeats in
proteins.
TRIPLET REPEAT EXPANSION DISEASES AND
MECHANISMS OF PATHOGENESIS
Over 20 different genes containing unstable TNRs have
been implicated in the pathogenesis of human neurologic-
al diseases collectively named TREDs [reviewed in (1)].
Expanded CTG, CGG, GAA and CAG repeats are
sources of degenerative changes leading to symptoms
associated with DM1, FXTAS, Friedreich’s ataxia
(FRDA) as well as HD and a series of SCAs (Figure 2).
These are typically late-onset inherited disorders and their
causative repeat mutations are located in different parts of
genes that primarily determine the number of potential
toxic entities. The adverse effect of non-coding mutations
in DM1 and FXTAS is principally determined by the ex-
pression of a mutant transcript (57–61), whereas the
toxicity of coding mutations is pronounced by the
presence of both RNA and protein, which harbor abnor-
mally lengthened repeats (11,62). In two other non-coding
repeat expansion disorders, FRDA and FXS, it is the di-
minished expression of speciﬁc proteins which triggers
pathogenesis as a result of inhibited or abortive transcrip-
tion across, respectively, expanded GAA and CGG
repeats (63–67).
Among well-studied mechanisms underlying TREDs
are: (i) toxic RNA gain-of-function caused by transcripts
harboring expanded CUG, CAG or CGG repeats
(2,61,68–70); (ii) toxic protein gain-of-function through
expression of polyglutamine (polyQ) tract encoded by
mutant CAG repeats (71,72); and (iii) aberrant loss-of-
transcript and loss-of-protein function caused by GAA
and CGG expansions (63–67). However, considering the
results of the most recent reports one can speculate that
the mechanistic complexity of pathogenesis in TREDs is
higher and more variable. The presence of non-ATG
initiated translation was recently reported by Ranum
and colleagues (13,73), and bidirectional transcription
through repeat regions was shown for several genes of
TREDs (74–76). The bidirectional transcription is not
only a source of sense and antisense transcripts, but also
leads to the generation of triplet repeat-derived siRNAs
targeting transcripts containing complementary repeats as
shown by the groups of Bonini (77) and Richards (78).
These results indicate the existence of novel toxic entities
that may give rise to new potential pathomechanisms.
Further studies will evaluate their importance to the
pathogenesis of speciﬁc TREDs.
STRUCTURES OF TRIPLET REPEATS IN TRED
TRANSCRIPTS
The involvement of mutant transcripts in the pathogenesis
of DM1, and its possible contribution to the pathogenesis
of FXTAS and polyQ diseases prompted researchers in
the past decade to take on the detailed structure examin-
ation of triplet repeat regions in numerous TRED tran-
scripts. A further argument for undertaking that effort
was the conviction that the treatments of TREDs aimed
at the allele-speciﬁc inhibition of mutant transcript or its
destruction by direct repeat targeting will beneﬁt from
having a deeper insight into the structure of the target.
The structural information gathered for ORNs (44,45)
and described earlier in this review was insufﬁcient for
this purpose, as it did not provide answers to questions
such as the following: what is the effect of repeat length on
structures formed by repeats? What is the contribution of
sequences ﬂanking repeats to the structure of the repeat
region? And what are the structural roles of various repeat
interruptions?
The ﬁrst study aimed at answering these questions was
performed on the DMPK transcript implicated in DM1
Figure 2. Expanded triplet repeats are located in different parts of transcripts. Depending on the location of expandable repeats, neurological disease
pathomechanisms can be divided into three groups. Repeats located in 50-UTR, 30-UTR or in introns cause diseases mainly via either loss of gene
function or RNA gain-of-function, whereas repeats present in open reading frames trigger degeneration via gain-of-protein function in conjunction
with RNA gain-of-function [in the ﬁgure legend, disease symbols (e.g. FXS), names of affected genes (e.g. FMR1), expanded repeat types and amino
acids encoded are indicated]. In SCA12 CAG expansion in 50-UTR also results in the elevated expression of the ppp2r2b protein (denoted by
asterisk); In SCA8 bidirectional transcription also results in toxic proteins (denoted by double asterisks).
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tion of representative normal alleles of TRED genes based
on population genotyping results; (ii) size selection of the
repeat region based on RNA structure prediction; and (iii)
PCR synthesis of DNA templates for in vitro transcrip-
tion, RNA synthesis, end labelling and structure probing
with the use of nucleases (80) and lead ions (81,82).
Normal length transcripts containing 5, 11 and 21 CUG
repeats revealed the conversion of a single-stranded repeat
region into semi-stable slippery hairpins upon increasing
the repeat length, whereas stable hairpins were formed by
expanded 49 CUG repeats (79). The ﬁnding that
double-stranded-like structures are formed by CUG
repeats in expanded transcripts was instrumental to the
later discovery that muscleblind-like 1 (MBNL1) protein
is sequestered by mutant DMPK transcripts in DM1
patient cells (83).
Similar in vitro structural analysis was further con-
ducted for the triplet repeat regions of the majority of
TRED transcripts and revealed their structural diversity.
The contribution of sequences ﬂanking the repeats to
repeat hairpin stabilization was shown for ATXN1 (84),
CACNA1A (85) and FMR1 (86) transcripts (Figure 3A).
In contrast, ﬂanking sequences did not inﬂuence the struc-
tures formed by repeats in DMPK (79), ATXN2 (87),
ATXN3 or ATN1 transcripts (85). In HTT and AR tran-
scripts, neighbouring repeats CCG and CUG, respect-
ively, interact with CAG repeat tracts to form hairpins
that have an unique composite architecture (88). It
should be recognized, however, that the structures
determined for triplet repeats in vitro may not fully recap-
itulate folding that occurs inside cells in the context of full-
length RNA and various RNA binding proteins. The
intracellular RNA structures and interactions, which
were out of reach for a long time, are now amenable for
investigation also for triplet repeats and on a
transcriptome-wide scale. Such methods as global
RACE (89), transcriptome-wide RNA structure probing
(90) and HITS-CLIP (HIgh-Throughput Sequencing of
CrossLinking and ImmunoPrecipitation products) (91)
allow detecting products of RNA cleavages by endogen-
ous nucleases or exogenous reagents, and determining
high-resolution maps of RNA–protein interaction in vivo.
In four TRED-related genes i.e. FMR1, ATXN1,
ATXN2 and TBP, the majority of the normal alleles
contain speciﬁc interruptions located within the repeat
tracts. These are AGG triplets disrupting CGG repeats
in the FMR1 gene, CAT triplets within CAG repeats in
the ATXN1 gene and CAA interruptions within CAG
repeats in both the ATXN2 and the TBP genes (87).
Such repeat interruptions in DNA have been shown to
function as protective elements, preventing pathogenic
repeat expansion (92). But what could be their functions
in transcripts? RNA structure probing revealed that AGG
interruptions within the CGG repeat of the FMR1 tran-
script prevent single hairpin structure formation by the
repeats (Figure 3B). Instead, branched hairpins are
formed that have the substituted base either in the side
loop or in an enlarged terminal loop, depending on the
location of the interruption (86). Similar structural roles
were demonstrated for CAU and CAA interspersions in
the ATXN1 (84) and ATXN2 (87) transcripts (Figure 3B)
and were predicted for the TBP transcript (87). It was
hypothesized that the AGG interruptions may protect
some premutation carriers from being prone to FXTAS
by shortening the length of the hairpin composed of pure
CGG repeats (86). In the cases of SCA1 and SCA2, rare
carriers of expanded interrupted repeats have not de-
veloped any disease, and the RNA structure of the
repeat region was found to be better correlated with
pathogenesis than the length of the polyQ tract (84,87).
These correlations suggested that RNA hairpin structure
plays a more general role in the pathogenesis of TREDs.
TRIPLET REPEAT RNA INTERACTION WITH
PROTEINS
The protein binding properties of TNR sequences have
been mostly studied in relevance to the toxic features of
mutant transcripts rather than in the context of the
putative normal functions of TNR RNA (83,93,94).
These studies took advantage of various methods to
Figure 3. Inﬂuence of sequences ﬂanking TNRs and repeat interrup-
tions on structures formed by TNRs in different TRED transcripts. (A)
In some transcripts, the repeats themselves (red line) form autonomous
hairpin structures that show slippage tendencies (two left panels). In
several other transcripts, sequences ﬂanking the repeat (dark gray line)
inﬂuence the stability of the structure leading to the ﬁxation of a single
conformation (middle panel). In HTT and AR transcripts, two con-
secutive repeat sequences (red and blue lines) together with ﬂanking
sequences form a single composite hairpin structure (two right
panels); (B) Sequences interrupting the triplet repeat region in the
ATXN1, ATXN2 and FMR1 transcripts strongly inﬂuence structure
formation. The interruptions can either break hairpin regularity or
induce the formation of branched structures in which interruptions
are predominantly present in terminal and internal hairpin loops.
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these interactions structurally. Most of this research has
dealt with CUG repeats. First, the CUGBP1 protein was
identiﬁed on the basis of its speciﬁc binding to single-
stranded (CUG)8 incubated in HeLa cell nuclear extract
(95). CUGBP1 is a member of the CELF (CUGBP and
ETR-3-like factors) protein family, which regulate a
number of post-transcriptional RNA processing steps
including alternative splicing (96,97). The electron micros-
copy examination of the in vitro binding of recombinant
CUGBP1 to transcripts containing expanded CUG
repeats revealed that the protein localizes only to the
base portion of the CUG repeat hairpin and its binding
is not proportional to CUG repeat length (98). Studies
have shown that CUGBP1 does not co-localize with
mutant transcripts in DM1 cells (99,100).
Swanson and colleagues succeeded in identifying the
RNA-binding protein, homologous to the Drosophila
mbl proteins which binds to CUG repeats in a
length-dependent manner and regulates alternative
splicing (83). This protein was later shown to co-localize
with mutant DMPK transcripts in a variety of DM1
patient cells and model organisms (99,101,102). Using
the yeast two hybrid system, MBNL1 was shown to
bind not only to CUG repeats but also to other types of
repeated sequences, including CAG repeats (93). A
ﬁlter-binding assay revealed a very similar in vitro
binding afﬁnity of MBNL1 to mutant CUG and CAG
repeats (103). Moreover, the analysis of ﬂuorescence
recovery after photobleaching (FRAP) indicated that the
afﬁnity of the GFP-MBNL1 fusion protein to long CUG
and CAG repeats is very similar in transfected cells (104).
Most recently, HeLa and neuroblastoma cells expressing
5, 30, 70 or 200 exogenous CUG or CAG repeats were
analyzed for colocalization repeat-containing transcripts
with endogenous MBNL1 (12). Mutant transcripts with
70 or 200 CUG or CAG repeats were found to form
nuclear inclusions that overlap with MBNL1. Other
studies investigated the ability of CUG and CAG
repeats to activate RNA-dependent protein kinase
(PKR), the known cellular sensor of long dsRNA (105).
CUG repeats of lengths with pathological consequences
showed some activation of the kinase in vitro, and
mutant CAG repeats of the HTT transcript were shown
to activate PKR in human HD brain tissues (106).
The architecture of a CUG repeat hairpin of mutant
length (54 repeats) in complex with MBNL1 was investi-
gated using chemical and enzymatic structure probing and
electron microscopy (103). MBNL1 multimers were
shown to form ring-like structures that bind to the stem
portion of the CUG repeat hairpin. The structures of very
short oligomers containing CUG motifs in complex with
MBNL1 were determined by crystallography, and the
results suggested that MBNL1 may efﬁciently bind
single-stranded CUG repeats (107). Very recently,
MBNL1 was shown to bind (CUG)17 and (CAG)17
ORNs with similar afﬁnity, whereas non-hairpin forming
repeats of the same lengths composed of AUG or UUA
repeats did not bind MBNL1 under the same assay con-
ditions (12).
Interactions between CGG repeats and proteins have
been recently investigated in cellular systems. Various
cell lines were transfected with plasmids expressing 20,
40, 60 or 100 CGG repeats, and only the expression of
long repeats supported the formation of nuclear aggre-
gates in some but not all of the cell lines tested (108).
These aggregates were shown to recruit the
RNA-binding proteins SAM68, hnRNP-G and MBNL1.
Earlier studies identiﬁed a number of other proteins that
co-localize with long CGG repeats. Hagerman and col-
leagues used ﬂuorescence-activated ﬂow sorting, mass
spectroscopy and immunohistochemistry to analyze the
protein composition of RNA-containing intranuclear in-
clusions formed in astrocytes and neurons of FXTAS
patients (109). These authors identiﬁed >20 proteins,
including Lamin A/C, vimentin, hnRNP-A2/B1 and
MBNL1. Furthermore, Pur alpha, hnRNP A2/B1 and
CUGBP1 were shown to bind CGG repeats in the
Drosophila model of FXTAS (94,110). The results of the
protein binding studies suggest that MBNL1 sequestration
by expanded CUG and CAG repeat transcripts is likely
caused by direct RNA–protein interactions (103), and that
SAM68 sequestration by expanded CGG repeats depends
rather on indirect interaction (108).
RNA-MEDIATED PATHOGENESIS TRIGGERED BY
TRIPLET REPEAT EXPANSION
The ability of mutant CNG repeats to form long hairpin
structures (44,79,98) is a signiﬁcant determinant of toxic
RNA-dependent pathogenesis in a number of TREDs.
TNRs of mutant length gain a toxic function by binding
essential proteins and consequently diminishing their func-
tional cellular levels (Figure 4). A characteristic feature of
the RNA–protein interactions in mutant TNR-expressing
cells is the formation of nuclear foci [reviewed in (111)] in
which sequestered proteins, such as MBNL1-3 and
SAM68, become immobilized. These aggregates cause
cells to develop degenerative changes that are manifested
through misregulated alternative splicing and embryonic
splicing patterns in adult tissues (108,112–114). In the fol-
lowing sections, we characterize the toxic effects of nuclear
aggregates in cells expressing mutant CUG, CGG and
CAG repeat RNA focusing on their adverse effect on al-
ternative splicing.
Cellular toxicity mediated by expanded CUG repeats in
DM1 and SCA8
DM1 was the ﬁrst neurological disorder in which the
nuclear retention of transcripts containing expanded
CUG repeats was detected (57,58). Although the reduced
expression of both DMPK and the neighboring gene SIX5
accompany the mutant transcript retention (115), the main
pathogenic mechanism is a deleterious gain-of-function of
mutant RNA harboring CUG repeats. Over the years, as
the number of DM1 model organisms has increased, the
evidence for an RNA-dominant mechanism has grown
stronger. The characteristic changes associated with
DM1 pathogenesis in skeletal and cardiac muscles have
been reproduced in transgenic mice and ﬂies by expressing
16 Nucleic AcidsResearch, 2012,Vol. 40,No. 1expanded CUG repeats (97,116,117). These similarities
have been correlated with an adverse inﬂuence of
mutant transcripts on RNA-binding proteins, i.e.
MBNL1 and CUGBP1, that causes misregulated alterna-
tive splicing in DM1 (Figure 4B) (83,101).
To date, several aberrantly spliced transcripts have been
identiﬁed that explain some of the phenotypic features of
DM1 pathogenesis. For example, skeletal muscle
hyperexitability (myotonia) and weakness have been
associated with the mis-splicing of the chloride channel
(CLCN1) (113,118–120) and the bridging integrator 1
(BIN1) (121) transcripts. Additionally, splicing alteration
of the insulin receptor (INSR) contributes to the insulin
resistance in DM1 muscle ﬁbers (112,122). Defects in the
cardiac functions are thought to be associated with the
aberrant splicing of the troponin T type 2 (cTNT) tran-
script (123–125). Spliceopathy also features a number of
central nervous system (CNS) transcripts including those
for the glutamate receptor, ionotropic N-methyl D-aspar-
tate 1 (NAMDAR1/GRIN1), amyloid beta precursor
protein (APP) and microtubule-associated protein tau
(MAPT) (68,126). Studies have shown that the
DM-speciﬁc aberrant splicing pattern is reproduced not
only in mice (102,127) and ﬂies (128,129) expressing the
DM1 mutation, but also in Mbnl1
E3/E3 knockout mice
(102) and in CUGBP1 overexpressing mice (127,130,131).
These ﬁndings provide further evidence for the prominent
roles played by these two splicing factors in DM1
pathogenesis.
An RNA gain-of-function mechanism by mutant CUG
repeats is also implicated in SCA8 pathogenesis. This
neurodegenerative disease primarily affects the cerebellum
and is caused by a CTG CAG repeat expansion that is
transcribed in both directions and gives rise to the anti-
sense non-coding CUG-harboring transcripts and
translated CAG-bearing transcripts (Figure 2). The later
transcripts undergo conventional translation that results
in polyQ protein and non-ATG translation (13) that
occurs across expanded CAG repeats in all reading
frames and gives rise to the homopolymeric proteins of
Figure 4. Dominant effects of toxic RNA repeats in different TREDs. (A) Mutant CUG and CAG repeat RNAs form nuclear foci (red) in DM1
and HD human ﬁbroblasts. RNA FISH was performed using ﬂuorescently labelled repeat probes: CAG in DM1 cells and CTG in HD cells, normal
cells were treated with either probe; (B) In normal cells, transcripts with short CNG repeats are exported from the nucleus and translated into
functional proteins (ﬁrst panel). Thus, the availability of nuclear splicing factors CUGBP1 (blue), MBNL1 (green) and SAM68 (orange) is not
compromised. In DM1 cells (second panel), the CUG
mut transcript is retained in the nucleus, where it sequesters MBNL1 and causes the abnormal
phosphorylation of CUGBP1, upregulating its nuclear levels. As a result, the incorrect splicing of several MBNL1- and CUGBP1-dependent
transcripts occurs (examples of misspliced transcripts are speciﬁed as green and blue, respectively). In HD cells (third panel), expanded CAG
repeat RNA partially sequesters MBNL1, but does not change the level of CUGBP1, which results in splicing abnormalities affecting some
MBNL1-dependent transcripts. The CAG
mut transcript is effectively translated into toxic polyQ protein (polyQ tract is indicated by a red line).
In FXTAS cells (fourth panel), the CGG
mut transcript colocalizes in the nucleus with SAM68 and MBNL1, but this colocalization does not occur via
direct RNA–protein interaction. The consequence of this interaction is the aberrant splicing of only SAM68-dependent transcripts (orange).
Moreover, FMR1 mRNA containing long CGG repeats in its 50-UTR is poorly translated.
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[reviewed in (73,132)]. Whereas protein products of the
sense transcripts build up as intranuclear inclusions that
are detected in human brain autopsy tissue and in the
brains of transgenic SCA8 mice (69), the nuclear retention
of mutant CUG transcripts is manifested by the formation
of RNA inclusions that colocalize with MBNL1 in
selected neurons in the cerebellum. This event is thought
to affect the alternative splicing of a number of CNS tran-
scripts including APP, MAPT, NMDAR1 and MBNL1,
which mimics aberrations observed in DM1 (68). In
addition, the SCA8 CUG repeat expansion transcripts
trigger splicing changes and increased expression of the
GABA-A transporter 4 (GAT4/Gabt4) due to the
dysregulation of MBNL/CELF regulated pathways in
the brain (69).
Toxicity mediated by expanded CGG and CAG repeat
RNAs
Strong evidence has been provided for the contribution of
an RNA gain-of-function mechanism also in the patho-
genesis of FXTAS and some of the polyglutamine dis-
orders (11,109). In these diseases, speciﬁc proteins are
sequestered into nuclear foci containing expanded CGG
and CAG repeats that cause the deviated splicing of
speciﬁc transcripts, which resembles DM1 pathogenesis
(Figure 4B). In FXTAS, the mis-splicing might affect
only transcripts regulated by proteins recruited early to
CGG repeat foci as shown by Charlet-Berguerand and
colleagues (108). In fact, in mutant CGG-expressing
cells, the only foci protein whose functional activity is
compromised is splicing factor SAM68, which is recruited
to RNA foci before hnRNP G and MBNL1.
Consequently, the misregulation of pre-mRNA alternative
splicing controlled by SAM68 is observed in CGG-trans-
fected cells and in FXTAS patients. An analysis of alter-
native splicing of the phospho-type-4 ATPase-11B
(ATP11B) pre-mRNA showed a splicing misregulation
in SAM68-depleted cells as measured by a signiﬁcant
decrease of exon-28B inclusion in comparison with
control samples (108).
Experimental evidence has shown that expansions of
CAG repeats in coding exons may convey pathogenic po-
tential not only to polyQ proteins, but also to transcripts
that harbor the repeat mutation. Initially, it was
demonstrated by Cooper and colleagues that in COSM6
cells the transient expression of 960 CAG repeats causes
nuclear retention of the expanded repeats (104).
Subsequent experimental evidence provided support for
the toxic capacity of mutant CAG repeat RNA in trans-
genic mice (11), worms (133) and the SCA3 Drosophila
model (62) as well as in human SCA3 and HD ﬁbroblasts
(12). However, because mutant CAG repeat-triggered al-
ternative splicing abnormalities were discovered very
recently, the scale of these effects and their roles in patho-
genesis has yet to be determined (Figure 4B). The most
recent results from our laboratory show that in human
HD and SCA3 ﬁbroblasts, the expression of endogenous
HTT and ATXN3 mutant transcripts causes the forma-
tion of CAG repeat foci and MBNL1 sequestration
(12,88), which in turn trigger the aberrant splicing of en-
dogenous sarco/endoplasmic reticulum Ca2+ ATPase 1
(SERCA1) and INSR transcripts. Similarly, expanded
but exogenous CAG repeats mimic CUG repeats in the
misregulation of alternative splicing, and in HeLa and
neuroblastoma cells both types of repeat RNA cause
defects in the processing of SERCA1, INSR, LIM
domain binding 3 (LDB3) and CLCN1 pre-mRNAs
(12). These results show that transcripts containing
expanded CAG repeats may contribute to the pathogen-
esis of HD, SCA3 and perhaps other polyglutamine
diseases.
EXPERIMENTAL THERAPIES DIRECTED AGAINST
EXPANDED REPEAT RNA
To date, three main strategies which use expanded repeat
RNA as a target have been tested as experimental
therapies for TREDs. The ﬁrst is based on degrading
mutant transcripts with RNA interference (RNAi) tools
or antisense oligonucleotides (AON); the second utilizes
repeat hairpin-speciﬁc small compounds or antisense
oligomers to inhibit pathogenic interactions between
repeat RNAs and nuclear proteins; and the third is
aimed at blocking toxic protein synthesis by binding
chemically modiﬁed antisense oligomers to repeats or by
targeting repeats with mutant siRNAs acting as miRNAs
(Figure 5). These strategies are aimed at destroying the
toxic agents of pathogenic pathways associated with
TREDs which involve either RNA, protein or both.
An important issue in therapies for TREDs that involve
repeat targeting reagents is the requirement for gene and
allele selectivity. Despite the fact, that there are numerous
mRNAs containing triplet repeats in human transcrip-
tome, the speciﬁc inhibition of mutant gene expression
by targeting repeat regions is a promising therapeutic
strategy for diseases caused by CAG and CUG repeat
expansion. Among the features used in designing selective
reagents are differences between normal and mutant tran-
scripts related to their repeat sequence lengths and struc-
tural properties as well as, in the case of DM, cellular
localization. The intended targets i.e. expanded repeats
are likely to form hairpin structures in cells which make
them both more prone (increased repeat length) and more
resistant (more stable structure) to interaction with target-
ing reagents in comparison with normal repeats. The ne-
cessity of selective inhibition of mutant allele expression
may not be equally important for all polyQ diseases;
nevertheless, preserving the expression of the protein
from normal allele seems to be an advantageous feature
of any therapeutic strategy.
Below, we describe the use of AON and RNAi reagents
as well as that of small compounds that speciﬁcally bind to
some repeat hairpins. According to their mechanism of
action, antisense reagents can be divided into two cate-
gories: ‘cutters’, which bind to complementary targets
and induce their cleavage taking advantage of RNaseH
or Argonaute 2 (AGO2) activities (AON or siRNA, re-
spectively), and ‘blockers’, which are oligomers that bind
to complementary targets, either alone or within protein
18 Nucleic AcidsResearch, 2012,Vol. 40,No. 1complexes, but do not induce the cleavage of their com-
plementary target. Examples of ‘blockers’ include peptide
nucleic acids (PNAs), locked nucleic acids (LNAs),
morpholino and miRNA-like acting duplexes (Figure 5).
The exact mechanisms by which different reagents
described below exert their activity are not yet known in
detail.
The degradation of mutant transcripts induced by
antisense oligonucleotides and RNAi triggers
Therapies for polyQ expansion diseases are aimed primar-
ily at reducing the level of the mutant protein. In addition,
mutant transcript downregulation may be desirable
because of its involvement in pathogenesis. RNAi
reagents require  20nt of complementary sequence for
efﬁcient silencing, which constitutes only 7 CAG repeats.
While the normal alleles of CAG-bearing transcripts
usually have 10–20 repeats, their mutant versions
contain 40–100 CAG repeats meaning that transcripts
from both alleles can be targeted by triplet repeat
siRNA duplexes. Moreover, only among annotated
human mRNAs, there are at least 50 transcripts contain-
ing CAG repeats and 30 with CUG repeats (29) being
potential targets for complementary AONs and RNAi
reagents.
RNA duplexes composed of CAG and CUG repeat
strands have been tested in cell culture for their ability
to silence HTT, AR, ATXN1 and ATXN3 transcripts.
The reagents used included 81-bp long synthetic CAG/
CUG RNA duplexes (134), 21-bp siRNA duplexes (135–
137) and shRNA (138), and all showed only a slight
silencing preference for mutant allele versus normal
allele. Both strands of CAG/CUG siRNA were found to
be active and silenced other transcripts also containing
complementary repeats causing a considerable loss of
the viability of human ﬁbroblasts (137). The CAG/CUG
siRNA induced some toxicity also in two Drosophila
models co-expressing elevated levels of expanded CTG
Figure 5. Therapeutic strategies aimed at targeting expanded triplet repeats in TRED transcripts. The left panel shows the main pathogenic agent in
diseases caused by expanded CUG or CAG repeats, which is either toxic RNA structure or toxic polyQ protein (both marked red). The middle and
right panels show the application of therapeutic AON, RNAi reagents and small compounds (indicated by a blue line) that speciﬁcally bind to CUG
or CAG repeat hairpins. Antisense reagents (AON) or siRNA called ‘cutters’ induce RNA degradation via RNaseH or AGO2 (middle panel),
whereas ‘blockers’ (PNA, LNA, morpholino and miRNA-like duplexes) bind to repeat RNA alone or within protein complexes and inhibit either
pathogenic RNA/protein interaction or translation of toxic polyQ proteins (right panel). See text for more details.
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experiments showed that hairpin structures which are
likely formed in cells by expanded CAG repeats did not
inhibit the activity of RNAi machinery directed at the
repeat region (88,137). As a result, mutant HTT tran-
scripts were efﬁciently targeted by CAG/CUG repeat
siRNAs and the repeated CAG sequence was cleaved at
numerous positions by AGO2 loaded with CUG repeat
guide strand (88).
In DM1, the degradation of expanded CUG repeat
transcripts was taken into consideration as possible
therapy (139). To destroy toxic RNA in cells, several
types of antisense reagents directed against CUG repeats
have been successfully tested. Retroviral expression of
149-nt RNA complementary to part of the DMPK 30-
UTR in DM1 myoblasts resulted in the 80% silencing of
the mutant DMPK transcript and a 50% reduction of the
normal transcript leading to the partial restoration of
some myoblast normal functions (140). Recently,
Furling and colleagues (141) engineered AONs by the
covalent linking of RNA sequences composed of 7, 11
or 15 CAG repeats to human U7 small nuclear RNA
for their delivery exclusively to the cell nucleus. The
lentiviral transduction of DM1 muscle cells with such con-
structs caused the speciﬁc silencing of  60–70% of mutant
DMPK mRNA without affecting normal DMPK tran-
scripts. In the treated cells, the number of nuclei contain-
ing toxic mutant CUG repeat foci was reduced and the
alternative splicing of several DM1-affected genes was sig-
niﬁcantly corrected (141).
In another study, Wansink and colleagues (142)
designed a short single-stranded (CAG)7 20-O-methyl
phosphorothioate oligonucleotide (PS58) to degrade tran-
scripts containing expanded CUG repeats. Such chemical
modiﬁcation of antisense oligomers is known to stabilize
duplex formed with a target sequence and increase the re-
sistance of AONs to cellular nucleases. PS58 decreased the
level of mutant DMPK transcripts by 50–90% in patient
myoblasts and in two DM1 mouse models, DM500 and
HSA
LR. Interestingly, the levels of other transcripts con-
taining short CUG repeats remained almost unchanged.
Local administration of this AON into the mouse skeletal
muscles reduced CUG repeat foci formation, partially
restored the alternative splicing of DM-speciﬁc exons
and signiﬁcantly reduced myotonia (142).
Antisense ‘blockers’ targeting triplet repeat RNA
Another straightforward therapeutic strategy is targeting
expanded CAG repeats in mutant transcripts to decrease
the production of toxic polyQ protein. Corey and col-
leagues have shown the allele-selective inhibition of toxic
protein translation in HD and SCA3 cells, using antisense
PNA and LNA oligomers composed of 7 CTG repeats
(136). After strong binding to complementary sequences,
these oligomers formed an impassable translational
barrier only in mutant transcripts (Figure 5). REP19N,
containing 19 PNA residues and modiﬁed by addition of
lysine residues at both termini, was the best allele-
discriminating reagent, with a speciﬁcity of inhibition at
least 10 times greater for mutant HTT protein translation
than for normal protein. Moreover, the translation of
other transcripts containing CAG repeats was not in-
hibited signiﬁcantly in PNA- and LNA-treated cells.
PNA oligomers were also tested for mutant ATXN3 trans-
lation inhibition; however, the maximum selectivity
achieved ( 5) was lower than that observed for HTT
(136). Oligomers with other chemical modiﬁcations such
as 20,4 0-constrained ethyl (cEt), carba-LNA, 20-O-
methoxyethyl (20-MOE) or 20-ﬂuoro have also been
shown to be promising blockers of mutant huntingtin
translation (143).
Another approach to RNA repeat-targeted inhibition of
mutant protein synthesis is the application of CAG/CUG
siRNA duplexes containing base substitutions at speciﬁc
positions causing mismatches with their mRNA targets.
This approach was tested in cultured HD ﬁbroblasts
(137,144) where several duplexes caused the efﬁcient trans-
lational inhibition of mutant huntingtin without
downregulation of its transcript. CAG/CUG duplexes
that form one or more mismatch with target sequences
most likely act as miRNAs despite the fact that their
target is located in the ORF. In most efﬁcient and selective
duplexes, the mismatched bases were present in the central
positions of the duplex (144) or in its 30 half (137).
Interestingly, transcriptional activation of the normal
HTT allele triggered by some of these duplexes occurred
concomitantly with the silencing of mutant allele (137).
This approach was also successfully used to target the
CAG repeat region of the mutant ATXN3 transcript,
although the selectivity of the reagents was lower than
that observed for HTT inhibition (145). Efforts are
being continued to develop this strategy further and to
obtain even more selective reagents.
The primary pathogenic effect of expanded CUG
repeats in DM1 is the sequestration of nuclear proteins,
including MBNL1. Therefore, preventing pathogenic
RNA–protein interactions is another approach to
reducing the toxic effects of mutant RNA. Proof of the
principle for this concept came from two independent
studies (146,147). Swanson and colleagues showed that
the overexpression of MBNL1 in an expanded CUG
repeat expressing HSA
LR mice can reverse the DM-like
phenotype (146). Thornton and colleagues using an anti-
sense morpholino oligomer composed of 25 CAG repeats
(CAG-25) inhibited the MBNL1/RNA interaction and dis-
rupted the complexes preformed in vitro (147) (Figure 5).
The morpholino modiﬁcation provides resistance to
cellular nucleases, high-stability duplexes with comple-
mentary targets and does not induce the cleavage of
targeted RNA. These features made it a promising agent
for in vivo therapy. The local administration of CAG-25
into the skeletal muscles of DM1 HSA
LR mice expressing
(CUG)250 RNA resulted in some molecular and pheno-
typic changes manifested through the signiﬁcant reduction
or elimination of nuclear CUG repeat foci and nearly a
complete reversion of abnormal splicing. These changes
were driven by the release of MBNL1 protein from seques-
tration and the restoration of ion channel function leading
to a signiﬁcant reduction of myotonia. Moreover, in
treated muscles, the mutant transcript was efﬁciently ex-
ported from the nucleus and translated in the cytoplasm.
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ﬁcial molecular effects were observed for as long as 14
weeks after a single injection and the expression of other
transcripts containing short CUG repeats was not affected
in skeletal muscle treated with CAG-25 (147).
Among the advantages of using repeat-targeting
reagents, both ‘cutters’ and ‘blockers’, the most important
is their potential application in several expansion-driven
diseases. In contrast, widely exploited gene-speciﬁc and
SNP-based strategies are applicable only for a fraction
of patients suffering from speciﬁc disorders. On the
other hand, the main challenge for repeat-targeting
strategies is directing the reagent speciﬁcally to the
mutant allele and leaving other repeat-containing tran-
scripts intact. At this time, all potential mRNA off-targets
are known (29), as discussed in ‘Triplet Repeats are
Frequent Motifs in Human Transcripts’ section of this
review, and their representatives may be tested along
with testing allele selectivity of silencing disease-causing
genes.
Small compounds that bind speciﬁcally to repeat
RNA hairpins
Another strategy considered for the treatment of some
TREDs is based on the identiﬁcation of small compounds
that interfere with pathogenic interactions between
expanded RNA repeats and proteins. Different groups
have used various approaches to identify ligands that spe-
ciﬁcally bind CUG and CAG repeat hairpins (148–153).
Screening a library of  11000 compounds yielded a few
molecules that showed selectivity for binding to either
short or expanded CUG repeat hairpins (148). These
ligands were able to prevent the CUG repeat/MBNL1
interaction in vitro with a low micromolar inhibition
constant. In another work, pentamidine and neomycin B
were shown to inhibit the interaction of short CUG repeat
RNA with MBNL1 in vitro (152). However, only the
former drug reversed the mis-splicing of two
DM1-affected transcripts and released MBNL1 from
nuclear inclusions in cells expressing 960 CUG repeats.
Additionally, high doses of pentamidine administered by
intraperitoneal injection into HSA
LR mice partially
reversed the mis-splicing of Serca1 and Clcn1
pre-mRNAs (152). In the most recent work, D-amino
acid hexapeptide (ABP1) was selected from a combinator-
ial peptide library screen in DM1 Drosophila model (153).
In vitro, ABP1 induced a switch of CUG hairpins to a
single-stranded conformation, whereas in Drosophila it
reduced CUG foci formation and suppressed
CUG-induced lethality. An intramuscular injection of
ABP1 into DM1 HSA
LR mice reversed muscle histopath-
ology and mis-splicing of Serca1 and Tnnt3.
The important issue regarding such compounds is their
binding speciﬁcity for RNA structures formed by repeated
sequences. To address this issue, Disney and colleagues
designed several multivalent ligands containing between
two and ﬁve Hoechst 33258 or kanamycin A derivatives
attached to a peptoid backbone (Figure 5) (150,151,154).
The modularly assembled ligands differed in their distance
between RNA-binding modules. All ligands were tested
both for their binding to CAG and CUG repeat tran-
scripts and for the inhibition of repeat RNA/MBNL1
interactions. The best multivalent ligands inhibited the
formation of RNA–protein complexes with inhibition
constant falling within the low nanomolar range. These
promising compounds have not yet been tested in
cellular or animal systems expressing expanded repeats;
however, their cell permeability has been demonstrated
(151).
FINAL REMARKS AND FUTURE PERSPECTIVES
In this article, we reviewed several aspects of research on
triplet repeat RNA. The occurrence of TNRs in human
transcripts was presented and the structural features of
both normal and pathogenic repeats were described. The
role of mutant TNRs as triggers of disease pathogenesis
and targets in experimental therapies for TREDs was dis-
cussed wherever relevant, from the perspective of RNA
structure.
At present, all annotated human mRNAs containing
triplet repeat tracts have been identiﬁed. However, only
a fraction of these transcripts is relatively well
characterized in terms of their TNR length polymorphism
and tissue expression. There is a much larger gap in our
knowledge of TNR RNAs if we take into consideration
various antisense transcripts from human genes as well as
sense and antisense transcripts from intergenic regions.
Nevertheless, even this gap may be ﬁlled soon as relevant
data may be mined by bioinformatics from several
recently completed and on-going large-scale sequencing
and expression proﬁling projects. We foresee that clearer
and a nearly complete view of human TNR RNA
repeatome is just on the horizon and this information
may become available soon for more focused research.
The efforts of several laboratories over the past decade
resulted in highly advanced structural characteristics of
TNR RNA, which was achieved using biochemical and
biophysical methods. TNRs may now be considered as a
part of human RN-ome that belongs to the best-
characterized structurally. We know which TNR types
form G-quadruplex structures, which tend to form more
stable and less stable hairpins and which are reluctant to
form any higher order structures. We also know that re-
peats having hairpin structure forming potential are over-
represented in exons and therefore are likely implicated in
some speciﬁc biological functions. At present, however,
the normal functions of TNRs in transcripts are very
poorly understood.
The speciﬁc functions of TNRs in RNA need to be ex-
pressed via interactions with proteins. But only a few
proteins that interact directly with normal length TNR
RNA have been identiﬁed thus far and their interactions
characterized. As described in this review, the length of
TNR RNA inﬂuences its protein binding properties and
only mutant TNRs are efﬁcient in speciﬁc protein seques-
tration. This raises a more general question about the
protein binding potential of normal TNR sequences.
One possible answer is that this potential is low and
only few proteins are capable of getting involved in such
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higher, but no systematic study was conducted thus far to
disclose it. In our opinion, further research focused on
ﬁnding additional proteins that act on relatively short
normal repeats and on expanded pathogenic repeats,
may help in a better understanding of the normal roles
of these sequences, and possibly in identifying new
pathways of pathogenesis in TREDs. High-throughput
analyses of triplet repeat RNAs associating with proteins
are also encouraged to identify their transcriptome-wide
interaction maps in cells.
Looking forward to any future structural studies of
TNR RNA, we predict that recent successes at resolving
crystal structures of short TNR duplexes may stimulate
efforts to determine high-resolution structures of longer
repeat TNRs and their complexes with various biological-
ly and therapeutically relevant ligands. Further progress in
this direction may help to better understand the
RNA-triggered pathogenic mechanisms in TREDs, and
promote a rational design of repeat-targeting therapeutic
agents.
Recent years have witnessed rapid progress in develop-
ing experimental therapies for TREDs in various cellular
and animal model systems. Several different concepts and
approaches have been successfully tested, making clinical
trials on humans a realistic prospect. Repeat-targeting
antisense reagents and RNA interference reagents acting
in miRNA fashion seem to be the most promising treat-
ment options. Efforts are now under way to better char-
acterize such reagents and optimize their gene selectivity
and allele selectivity, and minimize sequence-speciﬁc and
non-speciﬁc off-target effects.
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